FDCFF yields 6849.32% · PFE yields 6.20%● Live data
📍 FDCFF pulled ahead of the other in Year 1
Combined, FDCFF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of FDCFF + PFE for your $10,000?
Forum Energy Metals Corp. engages in the evaluation, acquisition, exploration, and development of natural resource properties in Canada and the United States. The company explores for energy metals, including copper, cobalt, uranium, palladium, nickel, platinum, and gold deposits. It holds 100% interests in the Fir Island uranium project covering an area of 20,463; the Janice Lake copper-silver project that covers an area of 39,943 hectares; the Love Lake nickel-copper-palladium-platinum project that covers an area of 32,135 hectares; the Grease River project covering an area of 10,528 hectares; the Wollaston project covering an area of 11,067 hectares; the Highlands project; the Glennie project; the Highrock uranium project; the Still Nickel project; and the Maurice Point uranium project that covers an area of 6,295 hectors located in Saskatchewan. It also holds a 65% interest in the Costigan uranium project; 75% interest in the Clearwater uranium project; 40% interest in the Henday uranium project; and 39.43% interest in the NW Athabasca located in Saskatchewan. In addition, the company also holds 100% interests in the Quartz Gulch property consist of 127 claims covering an area of 10.65 square kilometers located in Idaho; and 100% interests in the Nunavut Uranium project consist of 40 claims covering an area of 97,433 hectares located on the northeast of the Thelon Basin in Nunavut Territory. The company was formerly known as Forum Uranium Corp. and changed its name to Forum Energy Metals Corp. in February 2018. Forum Energy Metals Corp. was incorporated in 1987 and is headquartered in Vancouver, Canada.
Full FDCFF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.